Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease
10.1602/neurorx.1.2.263 Cite this article as: Rosas, H.D., Feigin, A.S. & Hersch, S.M. Neurotherapeutics (2004) 1: 263. doi:10.1602/neurorx.1.2.263 Summary
Trangenic mouse models and other screens are being used to identify potential therapeutic agents for use in clinical trials in Huntington’s disease (HD). The development of surrogate markers that can be used in clinical therapeutics is an active area of research. Because HD is relatively uncommon and only a portion of available subjects meet inclusion and exclusion criteria, therapeutic trials are limited by the availability of potential subjects as well as the relative insensitivity of the clinical measures used. Neuroimaging methods offer the potential to provide noninvasive, reproducible, and objective methods not only to better understand the disease process but also to follow in clinical studies to determine if a drug is effective in slowing down disease progression or perhaps even in delaying onset. Following is a review of the literature, which highlights the studies that have been published to date.
Key Words Huntington’s disease neuroimaging MRI PET biomarkers MRS Download to read the full article text References
Kremer B, Goldberg P, Andrews SE et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats.
N Engl J Med
330: 1401–1406, 1994.
Duyao M, Ambrose C, Myers R. Trinucleotide repeat length: instability and age of onset in Huntington’s disease.
4: 387–392, 1993.
Goldberg YP, Andrews SE, Theilmann J et al. Familial predisposition to recurrent mutations causing Huntington’s disease: genetic risk to sibs of sporadic cases.
J Med Genet
30: 987–990, 1993.
Nance M and the American College of Medical Genetics/American Society of Human Genetics Huntington’s Disease Genetic Testing Working Group. Laboratory guidelines for Huntington disease genetic testing.
Am J Hum Genet
62: 1243–1247, 1998.
The Huntington’ s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes.
72: 971–983, 1993.
Kieburtz K, MacDonald M, Shih C et al. Trinucleotide repeat length and progression of illness in Huntington’s disease.
J Med Genet
31: 872–874, 1994.
Feigin A, Kieburtz K, Bordwell K et al. Functional decline in Huntington’s disease.
10: 211–214, 1995.
Vonsattel JP, DiFiglia M. Huntington disease.
J Neuropathol Exp Neurol
57: 369–384, 1998.
Hersch SM. Huntington’s disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
Curr Opin Neurol
16: 501–506, 2003.
Sapp E, Schwarz C, Chase K et al. Huntingtin localization in brains of normal and Huntington’s disease patients.
42: 604–612, 1997.
Persichetti F, Ambrose GM, Ge P et al. Normal and expanded Huntington’s disease gene alleles produce distinguishable proteins due to translation across the CAG repeat.
1: 374–383, 1995.
Sharp AH, Loev SJ, Schilling G et al. Widespread expression of Huntington’s disease gene (IT15) protein product.
14: 1065–1074, 1995.
Trottier Y, Devys D, Imbert G et al. Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form.
10: 104–110, 1995.
Zuccato C, Ciammola A, Rigamonti D et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease.
293: 493–498, 2001.
Brinkman RR, Mezci MM, Theilmann J et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.
Am J Hum Genet
60: 1202–1210, 1997.
Wellington CL, Brinkman RR, O’Kusky JR et al. Toward understanding the molecular pathology of Huntington’s disease.
7: 979–1002, 1997.
Davies SW, Turmaine M, Lozens BA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
90: 537–548, 1997.
Gutekunst CA, Li SH, Yi A et al. Nuclear and neuropil aggregates in Huntington’ s disease: relationship to neuropathology.
19: 2522–2534, 1999.
Reddy PH, Williams M, Huang HM et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.
20: 198–202, 1998.
Andreassen OA, Dedeoglu A, Ferrante RJ et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease.
8: 479–491, 2001.
Andreassen OA, Ferrante RJ, Huang HM et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models in Huntington’s disease.
50: 112–117, 2001.
Andreassen OA, Ferrante RJ, Dedeoglu A et al. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease.
12: 3371–3373, 2001.
Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
6: 797–801, 2000.
Dedeoglu A, Kubilus JK, Jeitner TM et al. Therapeutic effects of cystamine in a murine model of Huntington’ s disease.
22: 8942–8950, 2002.
Ferrante RJ, Kubilus JK, Lee JL et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice.
23: 9418–9427, 2003.
Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency.
11: 1–4, 1996.
Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex.
Annu Rev Neurosci
9: 357–381, 1986.
Aylward EH, Li Q, Stine OC et al. Longitudinal change in basal ganglia volume in patients with Huntington’ s disease.
48: 394–399, 1997.
Rosas HD, Goodman J, Chen YI et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat.
57: 1025–1028, 2001.
Aylward EH, Codori AM, Rosenblatt A et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease.
15: 552–560, 2000.
Brandt J, Bylsma FW, Aylward EH et al. Impaired source memory in Huntington’s disease and its relation to basal ganglia atrophy.
J Clin Exp Neuropsychol
17: 868–877, 1995.
Rosas HD, Korosheta WJ, Chen YI et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.
60: 1615–1620, 2003.
Fischl B, Salut DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.
33: 341–355, 2002.
Ashburner J, Friston KJ. Why voxel-based morphometry should be used.
14: 1238–1243, 2001.
Thieben MJ, Duggins AJ, Good CD et al. The distribution of structural neuropathology in pre-clinical Huntington’s disease.
125: 1815–1828, 2002.
Rosas HD, Liu AK, Hersch S et al. Regional and progressive thinning of the cortical ribbon in Huntington’ s disease.
58: 695–701, 2002.
Brandt J, Shpritz B, Codori AM et al. Neuropsychological manifestations of the genetic mutation for Huntington’s disease in presymptomatic individuals.
J Int Neuropsychol Soc
8: 918–924, 2002.
Paulsen JS, Zhad H, Stout JC et al. Clinical markers of early disease in persons near onset of Huntington’ s disease.
57: 658–662, 2001.
Lawrence AD, Sahakian BJ, Hodges JR et al. Executive and mnemonic functions in early Huntington’s disease.
119: 1633–1645, 1996.
Lawrence AD, Watkins LH, Sahakian BJ et al. Visual object and visuospatial cognition in Huntington’s disease: implications for information processing in corticostriatal circuits.
123: 1349–1364, 2000.
Jahanshahi M, Brown RG, Marsden CD. A comparative study of simple and choice reaction time in Parkinson’s, Huntington’ s and cerebellar disease.
J Neurol Neurosurg Psychiatry
56: 1169–1177, 1993.
Witjes-Ane MN, Vegter-van der Vlis M, van Vugt JP et al. Cognitive and motor functioning in gene carriers for Huntington’s disease: a baseline study.
J Neuropsychiatry Clin Neurosci
15: 7–16, 2003.
Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington’s disease.
13: 703–706, 2002.
Aron AR, Schlaghecken F, Fletcher PC et al. Inhibition of sub-liminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington’s disease.
126: 713–723, 2003.
Kunig G, Leenders KL, Sanchez-Pernaute R et al. Benzodiazepine receptor binding in Huntington’s disease: [11C]flumazenil uptake measured using positron emission tomography.
47: 644–648, 2000.
Backman L, Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntinton’s disease and normal aging.
Scand J Psychol
42: 287–296, 2001.
Backman L, Robins-Wahlin TB, Lundin A et al. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes.
120: 2207–2217, 1997.
Lawrence AD, Weeks RA, Brooks DJ et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington’s disease.
121: 1343–1355, 1998.
Pavese N, Andrews TC, Brooks DJ et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study.
126: 1127–1135, 2003.
Ghilardi M, Ghez C, Dhawan V, Moeller J, Mentis M, Nakamura T et al. Patterns of regional brain activation associated with different forms of motor learning.
871: 127–145, 2000.
Feigin A, Ghilardi MF, Ghez CP et al. Increased cingulate activation during motor sequence learning in presymptomatic Huntington’s disease.
Neurology 58(Suppl 3): A333-A334, 2002.
Carbon M, Feigin A, Ghilardi MF et al. Longitudinal changes in the relationship between striatal D2 receptor binding and brain activation in preclinical Huntington’s disease.
Neurology 60(Suppl 1): A247-A248, 2003.
Hayden MR, Martin WR, Stoessl AJ et al. Positron emission tomography in the early diagnosis of Huntington’ s disease.
36: 888–894, 1986.
Kuhl DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan.
12: 425–434, 1982.
Kuwert T, Lange HW, Langen KJ et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease.
Brain Res 113: 1405–1423, 1990.
Young AB, Penney JB, Starosta-Rubinstein S et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline.
20: 296–303, 1986.
Young AB, Penney JB, Starosta-Rubinstein S et al. Normal caudate glucose metabolism in persons at risk for Huntington’s disease.
44: 254–257, 1987
Antonini A, Leenders KL, Spiegel R et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease.
119: 2085–2095, 1996.
Hayden MR, Hewitt J, Stoessl AJ et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s disease.
37: 1441–1447, 1987.
Kuwert T, Ganslandt T, Jansen P et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption.
J Comput Assist Tomogr
16: 789–794, 1992.
Mazziotta JC, Phelps ME, Pahl JJ et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’ s disease.
N Engl J Med
316: 357–362, 1987.
Feigin A, Fukuda M, Zgaljardic D et al. Metabolic brain networks in presymptomatic Huntington’s disease. Paper presented at the 15th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, Chicago, 2001.
Turjanski N, Weeks R, Dolan R et al. Striatal D1 and D2 receptor binding in patients with Huntington’ s disease and other choreas. A PET study.
118: 689–696, 1995.
Weeks RA, Piccini P, Harding AE et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s disease.
40: 49–54, 1996.
Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length.
43: 253–255, 1998.
Andrews TC, Weeks RA, Turjanski N et al. Huntington’s disease progression. PET and clinical observations.
122: 2353–2363, 1999.
Hussey D, Stewart P, Houle S et al. [C-11]raclopride striatal binding potential as a measure of Huntington’s disease progression: implications for prospective neuroprotective studies.
J Nucl Med 39(Suppl): 200P, 1998.
Storey E, Kowall NW, Finn SF et al. The cortical lesion of Huntington’s disease: further neurochemical characterization, and re-production of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.
32: 526–534, 1992.
Ellison DW, Beal MF, Martin JB. Amino acid neurotransmitters in postmortem human brain analyzed by high performance liquid chromatography with electrochemical detection.
J Neurosci Methods
19: 305–315, 1987.
Jenkins BG, Rosas HD, Chen 4C et al. 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers.
50: 1357–1365, 1998.
Koroshetz WJ, Jenkins BG, Rosen BR et al. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10.
41: 160–165, 1997.
Hoang TQ, Bluml S, Dubowitz DJ et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases.
50: 1033–1040, 1998.
Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A et al. Clinical correlation of striatal 1H MRS changes in Huntington’s disease.
53: 806–812, 1999.
Ferrante RJ, Andreassen OA, Jenkins BG et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease.
20: 4389–4397, 2000.
Lodi R, Schapira AH, Manners D et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and denta-torubropallidoluysian atrophy.
48: 72–76, 2000.
Ferrante RJ, Andreassen OA, Dedeoglu A et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease.
22: 1592–1599, 2002.
Hersch SM, Ferrante RJ. Neuropathology and pathophysiology of Huntington’s disease. In: Movement disorders. Neurologic principles and practice (Watts AL, Koller WC, eds), pp 503–518. Columbus, OH: McGraw-Hill, 1997.
© The American Society for Experimental NeuroTherapeutics, Inc 2004